Literature DB >> 22689280

[Pregabalin for the reduction of opiate withdrawal symptoms].

Nina Kämmerer1, Tagrid Lemenager, Martin Grosshans, Falk Kiefer, Derik Hermann.   

Abstract

Pregabalin is a substance which modulates monoamine release in "hyper-excited" neurons. It binds potently to the α2-δ subunit of calcium channels. Pilotstudies on alcohol- and benzodiazepine dependent patients reported a reduction of withdrawal symptoms through Pregabalin. To our knowledge, no studies have been conducted so far assessing this effect in opiate dependent patients. We report the case of a 43-year-old patient with Pregabalin intake during opiate withdrawal. Multiple inpatient and outpatient detoxifications from maintenance replacement therapy with Buprenorphine in order to reach complete abstinence did not show success because of extended withdrawal symptoms and repeated drug intake. Finally he disrupted his heroine intake with a simultaneously self administration of 300  mg Pregabaline per day and was able to control the withdrawal symptoms. In this time we did control the Pregabalin level in serum and urine in our outpatient clinic. In the course the patient reported that he could treat further relapse with opiate or opioids with Pregabalin successful. This case shows first details for Pregabalin to relief withdrawal symptoms in opiate withdrawal. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689280     DOI: 10.1055/s-0032-1305042

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  7 in total

Review 1.  Misuse and abuse of pregabalin and gabapentin: cause for concern?

Authors:  Fabrizio Schifano
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

2.  Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.

Authors:  Brendan J Snellgrove; Tilman Steinert; Susanne Jaeger
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

3.  Pregabalin abuse among opiate addicted patients.

Authors:  Martin Grosshans; Tagrid Lemenager; Christian Vollmert; Nina Kaemmerer; Rupert Schreiner; Jochen Mutschler; Xenija Wagner; Falk Kiefer; Derik Hermann
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

Review 4.  Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.

Authors:  Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

5.  A Novel Strategy for Attenuating Opioid Withdrawal in Neonates.

Authors:  Giovanni C Santoro; Samarth Shukla; Krishna Patel; Jakub Kaczmarzyk; Stergiani Agorastos; Sandra Scherrer; Yoon Young Choi; Christina Veith; Joseph Carrion; Rebecca Silverman; Danielle Mullin; Mohamed Ahmed; Wynne K Schiffer; Jonathan D Brodie; Stephen L Dewey
Journal:  J Addict Res Ther       Date:  2016-08-11

6.  Pregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam: examples from case reports.

Authors:  Basavaraja Papanna; Carlo Lazzari; Kapil Kulkarni; Sivasankar Perumal; Abdul Nusair
Journal:  Sleep Sci       Date:  2021 Apr-Jun

7.  A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.

Authors:  Rainer Freynhagen; Michael Serpell; Birol Emir; Ed Whalen; Bruce Parsons; Andrew Clair; Mark Latymer
Journal:  Pain Pract       Date:  2013-11-27       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.